Merck's Keytruda, or pembrolizumab, was approved by the FDA to treat pediatric and adult patients with refractory primary mediastinal large B-cell lymphoma who received two or more lines of therapy. The decision was backed by data from KEYNOTE-170 study, in which Keytruda treatment achieved a 45% response rate and a complete response rate of 11%.
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.